Polymorphic mixture of rifaximin and its use for the preparation of solid formulations

Abstract

A Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15±3.

1 - 13 . (canceled) 
     
     
         14 . A Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15±3, characterized by an X-Ray spectrum with characteristic 2theta values at about: 5.32, 5.78, 6.50, 7.24, 7.82, 8.80, 10.50, 11.02, 11.58, 13.08, 14.42, 17.32, 17.68, 18.58, 19.52, 21.04, 21.60, and 21.92. 
     
     
         15 . A pharmaceutical composition comprising the polymorphic mixture of Rifaximin of  claim 14  and a vehicle, excipient, or formulative ingredient. 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the pharmaceutical composition is a solid pharmaceutical composition. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the pharmaceutical composition is a film coated tablet. 
     
     
         18 . The pharmaceutical composition of  claim 15 , wherein the pharmaceutical composition comprises 550 mg of Rifaximin α/β polymorphic mixture of 85/15±3. 
     
     
         19 . The pharmaceutical composition of  claim 15 , wherein the pharmaceutical composition further comprises excipients. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the excipients comprise cellulose microcrystalline, sodium starch glycolate, glyceryl palmitostearate, hydrated silicon dioxide, and talc. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein the pharmaceutical composition further comprises polyvinyl alcohol, polyethylene glycol, titanium dioxide, and red iron oxide. 
     
     
         22 . The pharmaceutical composition of  claim 21 , wherein the pharmaceutical composition has a hardness of 18.49±1.30 Kp, a thickness of about 5.48±0.06 mm, a friability of about 0.058%, and a disintegration in purified water at 37° C. of about 1′20″. 
     
     
         23 . A tablet, comprising the Rifaximin polymorphic mixture of  claim 14  and a film coating. 
     
     
         24 . A Rifaximin polymorphic mixture of α/β form in a relative ratio of 85/15±3, characterized by an X-Ray spectrum with characteristic 2theta values at about 5.32, 5.78, 6.50, 7.24, 7.82, 8.80, 10.50, 11.02, 11.58, 13.08, 14.42, 17.32, 17.68, 18.58, 19.52, 21.04, 21.60, and 21.92, wherein said rifaximin polymorphic mixture is produced by drying wet Rifaximin at atmospheric pressure, at a temperature between 38 and 42° C. to reach a final water content of 6±2%.